EC approves Diurnal's Alkindi
Diurnal Group plc (LSE:DNL) said the European Commission approved Alkindi (Infacort) as a replacement therapy to treat adrenal insufficiency in individuals less than 18 years old. Diurnal plans to launch Alkindi in 2Q18, but told BioCentury it was "too early" to discuss pricing.
Alkindi is a dry granule formulation of hydrocortisone.
User Sign in
Trial Subscription
Get a 4-week free trial subscription to BioCentury Extra
Article Purchase
Purchase this article for limited one-time distribution and website posting
$750 USD
